Merus N.V.

MRUS Nasdaq CIK: 0001651311

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation Netherlands
Business Address YALELAAN 62, 3584 CM UTRECHT, DE,
Mailing Address YALELAAN 62, 3584 CM UTRECHT, DE,
Phone 31 030 253 8800
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2024

$782.69M
Total Assets
$134.77M
Total Liabilities
$647.93M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13D/A Beneficial ownership amendment December 30, 2025 View on SEC
4 Insider stock transaction report December 30, 2025 View on SEC
8-K Current report of material events December 30, 2025 View on SEC
4 Insider stock transaction report December 29, 2025 View on SEC
4 Insider stock transaction report December 22, 2025 View on SEC
SCHEDULE 13D Beneficial ownership report (>5%) December 19, 2025 View on SEC
4 Insider stock transaction report December 18, 2025 View on SEC
3 Initial insider ownership report December 18, 2025 View on SEC
4 Insider stock transaction report December 12, 2025 View on SEC
4 Insider stock transaction report December 12, 2025 View on SEC

Material Events

8-K Acquisition December 30, 2025
High Impact
  • Merus N.V. has been acquired by Genmab A/S through its subsidiary.
  • Genmab bought almost all of Merus's common shares for $97.00 each in cash.
View Analysis
8-K Acquisition December 12, 2025
High Impact
  • Merus N.V. has been acquired by Genmab A/S through one of its subsidiaries.
  • Genmab purchased almost all of Merus's shares for $97.00 per share in cash.
View Analysis
8-K Acquisition December 9, 2025
High Impact
  • Merus N.V. shareholders approved proposals related to the company's acquisition by Genmab A/S.
  • Genmab A/S is acquiring all of Merus's outstanding shares for $97.00 per share in cash.
View Analysis

Insider Trading

STRONG BUY 2 insiders 13 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.